29.05.2024 - Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year .
Direct Segment Net Sales of $139 Million Up 16% versus Pre-pandemic Fiscal 2020
Reaches 508K JRNY® Members During Q4 Fiscal 2023, Up 56% versus Q4 Fiscal 2022
Adjusted EBITDA Loss Reduced by. | May 23, 2023
22.05.2023 - Investigational New Drug (IND) application and Clinical Trial Application (CTA) for IMVT-1402 cleared by the FDA and MEDSAFE, respectivelyPhase 1 clinical trial in healthy subjects initiated in New ZealandPhase 2 proof-of-concept clinical trial of .
Revenues for the quarter ended March 31, 2023 total $4.3 billion, net loss is $737 million, adjusted EBITDA is $476 million, and adjusted pretax loss is $61 million
Fiscal year 2023 revenues. | May 16, 2023